Carperitide (CAS 89213-87-6) is a high-purity cardioprotective API, specifically a synthetic form of human atrial natriuretic peptide (ANP), designed to treat acute heart failure. Its unique peptide molecular structure enables it to selectively bind to natriuretic peptide receptors, regulating water and electrolyte balance while dilating blood vessels to reduce cardiac preload and afterload.
With strict quality control, this product meets pharmaceutical-grade standards, ensuring stable molecular activity and consistent efficacy in every batch. It is primarily used in formulating injectable medications for clinical scenarios, such as acute decompensated heart failure (ADHF) with volume overload, effectively relieving symptoms like dyspnea and edema and improving cardiac function.
For pharmaceutical manufacturers and research institutions focusing on cardiovascular therapeutics, this cardioprotective API offers reliable performance, high purity, and compliance with global pharmacopeia requirements. It eliminates the risk of impurities affecting drug safety, supporting the development of effective treatments for acute heart failure and addressing critical unmet medical needs in cardiovascular care.
